Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report.

IrAE should be considered when pericarditis develops after the administration of ICI even after a long period from its initiation. Infliximab rescue therapy may be considered as a 2nd-line therapy for steroid-refractory irAE pericarditis even with constrictive physiology.